OSE Immunotherapeutics SA (OSE.PA)
EUR 7.17
(-1.38%)
EUR 7.17
(-1.38%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 45.8 Million EUR | 2.25% |
| 2022 | 44.79 Million EUR | 20.63% |
| 2021 | 37.13 Million EUR | 90.29% |
| 2020 | 19.51 Million EUR | 69.97% |
| 2019 | 11.48 Million EUR | 157.42% |
| 2018 | 4.46 Million EUR | -8.7% |
| 2017 | 4.88 Million EUR | 173.82% |
| 2016 | 1.78 Million EUR | 82.04% |
| 2015 | 980 Thousand EUR | -16.81% |
| 2014 | 1.17 Million EUR | 2.7% |
| 2013 | 1.14 Million EUR | 38.03% |
| 2012 | 831 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 41.07 Million EUR | 0.0% |
| 2023 FY | 45.8 Million EUR | 2.25% |
| 2023 Q2 | 43.75 Million EUR | 0.0% |
| 2023 Q4 | 45.8 Million EUR | 0.0% |
| 2022 FY | 44.79 Million EUR | 20.63% |
| 2022 Q4 | 44.79 Million EUR | 0.0% |
| 2022 Q2 | 35.77 Million EUR | 0.0% |
| 2021 FY | 37.13 Million EUR | 90.29% |
| 2021 Q4 | 37.13 Million EUR | 0.0% |
| 2021 Q2 | 23.92 Million EUR | 0.0% |
| 2020 Q4 | 19.51 Million EUR | 0.0% |
| 2020 FY | 19.51 Million EUR | 69.97% |
| 2020 Q2 | 19.82 Million EUR | 0.0% |
| 2019 FY | 11.48 Million EUR | 157.42% |
| 2019 Q4 | 11.48 Million EUR | 0.0% |
| 2019 Q2 | 6.98 Million EUR | 0.0% |
| 2018 FY | 4.46 Million EUR | -8.7% |
| 2018 Q4 | 4.45 Million EUR | 0.0% |
| 2018 Q2 | 4.75 Million EUR | 0.0% |
| 2017 FY | 4.88 Million EUR | 173.82% |
| 2017 Q2 | 3.87 Million EUR | 0.0% |
| 2017 Q4 | 4.87 Million EUR | 0.0% |
| 2016 Q2 | 2.17 Million EUR | 0.0% |
| 2016 FY | 1.78 Million EUR | 82.04% |
| 2016 Q4 | 1.77 Million EUR | 0.0% |
| 2015 FY | 980 Thousand EUR | -16.81% |
| 2015 Q2 | 1.34 Million EUR | 0.0% |
| 2015 Q4 | 980 Thousand EUR | 0.0% |
| 2014 FY | 1.17 Million EUR | 2.7% |
| 2014 Q4 | 1.17 Million EUR | 0.0% |
| 2014 Q2 | 1.15 Million EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 Q3 | - EUR | 0.0% |
| 2013 Q4 | 1.14 Million EUR | 0.0% |
| 2013 FY | 1.14 Million EUR | 38.03% |
| 2012 FY | 831 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -1251.062% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 17.422% |
| Adocia SA | 13.08 Million EUR | -249.947% |
| Aelis Farma SA | 4.03 Million EUR | -1034.25% |
| Biophytis S.A. | 8.27 Million EUR | -453.821% |
| Advicenne S.A. | 17.42 Million EUR | -162.846% |
| genOway Société anonyme | 7.23 Million EUR | -533.187% |
| IntegraGen SA | 1.12 Million EUR | -3972.159% |
| Medesis Pharma S.A. | 1.2 Million EUR | -3716.75% |
| Neovacs S.A. | 650 Thousand EUR | -6946.308% |
| NFL Biosciences SA | 62.17 Thousand EUR | -73565.841% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -951.323% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -1585.819% |
| Sensorion SA | 2.86 Million EUR | -1496.528% |
| Theranexus Société Anonyme | 3.64 Million EUR | -1157.226% |
| TME Pharma N.V. | 1.16 Million EUR | -3828.045% |
| Valbiotis SA | 6.87 Million EUR | -565.906% |
| TheraVet SA | 1.15 Million EUR | -3848.815% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -409.013% |
| argenx SE | 18.1 Million EUR | -152.97% |
| BioSenic S.A. | 28.16 Million EUR | -62.64% |
| Celyad Oncology SA | 902 Thousand EUR | -4977.716% |
| DBV Technologies S.A. | 13.01 Million USD | -251.812% |
| Galapagos NV | 9.59 Million EUR | -377.293% |
| Genfit S.A. | 70.17 Million EUR | 34.736% |
| GeNeuro SA | 7.73 Million EUR | -491.912% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -765.149% |
| Innate Pharma S.A. | 39.89 Million EUR | -14.81% |
| Inventiva S.A. | 37.4 Million EUR | -22.44% |
| MaaT Pharma SA | 14.07 Million EUR | -225.407% |
| MedinCell S.A. | 58.96 Million EUR | 22.32% |
| Nanobiotix S.A. | 50.56 Million EUR | 9.422% |
| Onward Medical N.V. | 16.87 Million EUR | -171.429% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -234.625% |
| Oxurion NV | 12.33 Million EUR | -271.339% |
| Pharming Group N.V. | 155.29 Million EUR | 70.507% |
| Poxel S.A. | 46.9 Million EUR | 2.343% |
| GenSight Biologics S.A. | 18.42 Million EUR | -148.54% |
| Transgene SA | 1.25 Million EUR | -3543.675% |
| Financière de Tubize SA | 79.2 Million EUR | 42.17% |
| UCB SA | 3.03 Billion EUR | 98.492% |
| Valneva SE | 208.81 Million EUR | 78.066% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -120428.947% |